Video

Dr. Jhaveri Discusses a Basket Trial of Taselisib in Solid Tumors

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a basket trial of taselisib in patients with PIK3CA-mutated locally advanced or metastatic solid tumors.

Jhaveri says that taselisib is a potent, selective, oral inhibitor of class I PI3Kα, γ, and δ isoforms. In a phase I basket study (NCT01296555), the PI3K inhibitor taselisib was given to patients with PIK3CA-mutated solid tumors who had progressed after, or did not response to, at least 1 prior treatment.

There are 11 cohorts of patients with various solid tumors in the basket trial including endometrial, bladder, head and neck squamous cell carcinoma, cervical, gastric or gastroesophageal junction, small cell lung, triple-negative breast, colorectal, squamous, ovarian, and patients with tumors not otherwise specified. Patients on the study received either 4 mg or 6 mg of taselisib daily. The primary endpoint is safety and tolerability, with a secondary endpoint of antitumor activity.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School